The Lausanne Branch focuses primarily on tumor immunology and immunotherapy. This includes the mechanisms by which tumors thwart immune attack and the development of novel immunotherapies.
The Ludwig Lausanne Branch is primarily dedicated to the study of tumor immunology and the design and development of novel immunotherapies. We are especially focused on immunotherapies that are tailored to an individual patient’s cancer—such as dendritic cell vaccines and therapies that involve the engineering and reinfusion of a patient’s T cells. We also focus on developing technologies to standardize and streamline such personalized therapies, which will be essential to their wider deployment. Basic research in our laboratories is similarly tailored to support our program in immunotherapy. Aside from tumor immunology, it includes the exploration of the tumor microenvironment, systems biology, cancer cell metabolism and the development of antibody and computational biology technologies. Our Lausanne Branch is an integral part of the Department of Oncology of the University Hospital of Lausanne and a founding partner of the Swiss Cancer Center Léman.
Ludwig Institute for Cancer Research, Lausanne
Chemin des Boveresses 155
Épalinges, VD, CH, 1066
T (41) 21 314 06 24
F (41) 21 692 59 95